A Phase 3 interventional study of Gemcitabine and Docetaxel in Metastatic Breast Cancer (MBC), sponsored by Eli Lilly and Company. Completed at 34 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-27.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.
Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 56th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2005, is one of 51 in phase 3, and was the 97th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai JMT-Bio Inc. · Sites in China
Ages 18+
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 178 · Phase 3 55 · Phase 4 5
First in 1993; this study’s year is marked. 19 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 248 interventional studies. Of the 207 that completed or were terminated, 58 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 264 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 23rd largest by enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2005, is one of 16 in phase 3, and was the 27th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing docetaxel in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747338Phase 3Shanghai JMT-Bio Inc.A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | 2026-12-16 |
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 264 studies testing docetaxel in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Multi-center, randomized Phase III study. 4 arms. 360 Patient to enroll. Purpose is evaluate time to progression disease (PD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Docetaxel and Gemcitabine (Tri-weekly)
Drug: Gemcitabine · Drug: Docetaxel
Paclitaxel and Gemcitabine (Tri-weekly)
Drug: Gemcitabine · Drug: Paclitaxel
Docetaxel and Gemcitabine (Weekly)
Drug: Gemcitabine · Drug: Docetaxel
Paclitaxel and Gemcitabine (Weekly)
Drug: Gemcitabine · Drug: Paclitaxel
Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions). Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Also known as: LY188011, Gemzar
Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Time to Progressive Disease (TTPD) by Treatment Schedule
TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.
Time frame: Baseline up to 49.84 months
Time to Progressive Disease (TTPD) by Treatment Drug
TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.
Time frame: Baseline up to 49.84 months
Overall Survival (OS) by Treatment Schedule
OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).
Time frame: Baseline up to 51.64 months
Overall Survival (OS) by Treatment Drug
OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).
Time frame: Baseline up to 51.64 months
Overall Response Rate (ORR) by Treatment Schedule
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.
Time frame: Baseline up to 49.84 months
Overall Response Rate(ORR) by Treatment Drug
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.
Time frame: Baseline up to 49.84 months
Number of Participants With Serious and Nonserious Adverse Events (AEs)
Summary tables of serious adverse events (SAEs) and all other nonserious AEs are located in the Reported Adverse Event Module.
Time frame: Baseline up to 51.64 months
Quality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at Beginning of 3-Week or 4-Week Cycle
RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL by treatment arm are provided. Arms A (Docetaxel and Gemcitabine 3 Weekly) and B (Paclitaxel and Gemcitabine 3 Weekly) were assessed every 3 weeks. Arms C (Docetaxel and Gemcitabine Weekly) and D (Paclitaxel and Gemcitabine Weekly) were assessed every 4 weeks.
Time frame: Baseline up to 51.64 months
Quality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at 30-Day Post-therapy Visit
RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL (using the 7-point scale) by treatment arm are provided.
Time frame: Baseline up to 51.64 months
| Milestone | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) |
|---|---|---|---|---|
| Started | 60 | 64 | 58 | 59 |
| Completed | 18 | 24 | 14 | 19 |
| Not completed | 42 | 40 | 44 | 40 |
| Withdrew: Adverse event (study related) | 1 | 1 | 2 | 1 |
| Withdrew: Adverse event (not study related) | 3 | 3 | 4 | 7 |
| Withdrew: Death (study disease) | 1 | 4 | 0 | 0 |
| Withdrew: Death (not study related) | 2 | 0 | 0 | 0 |
| Withdrew: Death (study drug toxicity) | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Entry criteria exclusion | 0 | 1 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 4 | 5 | 2 |
| Withdrew: Physician decision | 7 | 8 | 7 | 6 |
| Withdrew: Satisfactory response | 2 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 18 | 18 | 25 | 23 |
TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.
| months | Treatment Schedule (Weekly) | Treatment Schedule (3 Weekly) |
|---|---|---|
| Time to Progressive Disease (TTPD) by Treatment Schedule | 8.33 (6.19 to 10.16) | 7.51 (5.93 to 8.33) |
OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).
| months | Treatment Schedule (Weekly) | Treatment Schedule (3 Weekly) |
|---|---|---|
| Overall Survival (OS) by Treatment Schedule | 21.11 (17.28 to 26.75) | 20.95 (18.92 to 33.21) |
OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).
| months | Treatment Drug (Docetaxel) | Treatment Drug (Paclitaxel) |
|---|---|---|
| Overall Survival (OS) by Treatment Drug | 19.11 (16.59 to 24.00) | 23.80 (19.38 to 31.97) |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.
| percentage of responses | Treatment Schedule (Weekly) | Treatment Schedule (3 Weekly) |
|---|---|---|
| ORR (Complete Response or Partial Response) | 50.43 | 33.06 |
| Complete Response | 6.84 | 5.65 |
| Partial Response | 43.59 | 27.42 |
| Stable Disease | 23.93 | 40.32 |
| Progressive Disease | 21.37 | 12.90 |
| Not Available | 0.85 | 1.61 |
| Not Assessed | 3.42 | 12.10 |
TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.
| months | Treatment Drug (Docetaxel) | Treatment Drug (Paclitaxel) |
|---|---|---|
| Time to Progressive Disease (TTPD) by Treatment Drug | 7.74 (5.57 to 9.80) | 7.80 (6.20 to 8.72) |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.
| percentage of responses | Treatment Drug (Docetaxel) | Treatment Drug (Paclitaxel) |
|---|---|---|
| ORR (Complete Response or Partial Response) | 43.2 | 39.8 |
| Complete Response | 5.08 | 7.32 |
| Partial Response | 38.14 | 32.52 |
| Stable Disease | 32.20 | 32.52 |
| Progressive Disease | 17.80 | 16.26 |
| Not Available | 0.85 | 1.63 |
| Not Assessed | 5.93 | 9.76 |
Summary tables of serious adverse events (SAEs) and all other nonserious AEs are located in the Reported Adverse Event Module.
| participants | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) |
|---|---|---|---|---|
| SAEs | 9 | 10 | 7 | 11 |
| Nonserious AEs | 57 | 58 | 53 | 56 |
RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL by treatment arm are provided. Arms A (Docetaxel and Gemcitabine 3 Weekly) and B (Paclitaxel and Gemcitabine 3 Weekly) were assessed every 3 weeks. Arms C (Docetaxel and Gemcitabine Weekly) and D (Paclitaxel and Gemcitabine Weekly) were assessed every 4 weeks.
| participants | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) |
|---|---|---|---|---|
| 1=Excellent | 3 | 1 | 2 | 4 |
| 2=Good | 13 | 13 | 9 | 5 |
| 3=Moderately Good | 6 | 8 | 9 | 9 |
| 4=Neither Good Nor Bad | 6 | 7 | 6 | 7 |
| 5=Rather Poor | 2 | 3 | 3 | 6 |
| 6=Poor | 0 | 3 | 7 | 2 |
| 7=Extremely Poor | 0 | 3 | 0 | 1 |
| No Response | 30 | 26 | 22 | 25 |
RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL (using the 7-point scale) by treatment arm are provided.
| participants | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) |
|---|---|---|---|---|
| 1=Excellent | 0 | 0 | 0 | 0 |
| 2=Good | 7 | 7 | 2 | 4 |
| 3=Moderately Good | 2 | 6 | 3 | 2 |
| 4=Neither Good Nor Bad | 3 | 6 | 0 | 3 |
| 5=Rather Poor | 0 | 1 | 1 | 1 |
| 6=Poor | 2 | 0 | 1 | 2 |
| 7=Extremely Poor | 1 | 0 | 2 | 0 |
| No Response | 45 | 44 | 49 | 47 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Docetaxel and Gemcitabine (Tri-weekly) | — | 9/59 (15.3%) | 57/59 (96.6%) |
| Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | — | 10/62 (16.1%) | 58/62 (93.5%) |
| Arm C: Docetaxel and Gemcitabine (Weekly) | — | 7/58 (12.1%) | 53/58 (91.4%) |
| Arm D: Paclitaxel and Gemcitabine (Weekly) | — | 11/59 (18.6%) | 56/59 (94.9%) |
| Event | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 4/59 | 1/62 | 0/58 | 1/59 |
| AnaemiaBlood and lymphatic system disorders | 0/59 | 1/62 | 0/58 | 2/59 |
| DiarrhoeaGastrointestinal disorders | 2/59 | 0/62 | 1/58 | 0/59 |
| AstheniaGeneral disorders | 0/59 | 0/62 | 1/58 | 2/59 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/59 | 0/62 | 0/58 | 0/59 |
| Oedema peripheralGeneral disorders | 0/59 | 0/62 | 1/58 | 0/59 |
| BronchitisInfections and infestations | 0/59 | 0/62 | 1/58 | 0/59 |
| Device related infectionInfections and infestations | 0/59 | 0/62 | 1/58 | 0/59 |
| Meningitis pneumococcalInfections and infestations | 0/59 | 0/62 | 1/58 | 0/59 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/59 | 0/62 | 1/58 | 0/59 |
| Event | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 50/59 | 33/62 | 20/58 | 38/59 |
| NauseaGastrointestinal disorders | 25/59 | 21/62 | 20/58 | 21/59 |
| PyrexiaGeneral disorders | 17/59 | 16/62 | 23/58 | 17/59 |
| AlopeciaSkin and subcutaneous tissue disorders | 22/59 | 18/62 | 14/58 | 16/59 |
| DiarrhoeaGastrointestinal disorders | 18/59 | 11/62 | 21/58 | 14/59 |
| LeukopeniaBlood and lymphatic system disorders | 21/59 | 9/62 | 14/58 | 13/59 |
| Alanine aminotransferase increasedInvestigations | 11/59 | 14/62 | 17/58 | 20/59 |
| AstheniaGeneral disorders | 17/59 | 18/62 | 18/58 | 15/59 |
| FatigueGeneral disorders | 15/59 | 12/62 | 13/58 | 18/59 |
| AnaemiaBlood and lymphatic system disorders | 12/59 | 10/62 | 12/58 | 17/59 |
| Age Continuous(years) | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) | Total |
|---|---|---|---|---|---|
| Mean | 56.58 ± 10.21 | 56.31 ± 9.84 | 55.78 ± 8.99 | 54.66 ± 10.04 | 55.85 ± 9.76 |
| Sex: Female, Male(Participants) | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) | Total |
|---|---|---|---|---|---|
| Female | 60 | 64 | 58 | 59 | 241 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) | Total |
|---|---|---|---|---|---|
| Caucasian | 58 | 63 | 58 | 59 | 238 |
| Other | 2 | 1 | 0 | 0 | 3 |
| Region of Enrollment(participants) | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) | Total |
|---|---|---|---|---|---|
| Italy | 60 | 64 | 58 | 59 | 241 |
| Menopausal Status(participants) | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) | Total |
|---|---|---|---|---|---|
| Premenopausal | 19 | 17 | 16 | 21 | 73 |
| Postmenopausal | 41 | 47 | 42 | 38 | 168 |
| Previous Hormonal Therapy(participants) | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) | Total |
|---|---|---|---|---|---|
| Yes | 44 | 48 | 40 | 46 | 178 |
| No | 16 | 16 | 17 | 13 | 62 |
| Unknown | 0 | 0 | 1 | 0 | 1 |
| Presence or Absence of Visceral Metastases(participants) | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) | Total |
|---|---|---|---|---|---|
| Absence | 19 | 19 | 16 | 23 | 77 |
| Presence | 41 | 45 | 42 | 36 | 164 |
| Number of Participants with Previous Adjuvant/Neoadjuvant Taxane Therapy(participants) | Arm A: Docetaxel and Gemcitabine (Tri-weekly) | Arm B: Paclitaxel and Gemcitabine (Tri-weekly) | Arm C: Docetaxel and Gemcitabine (Weekly) | Arm D: Paclitaxel and Gemcitabine (Weekly) | Total |
|---|---|---|---|---|---|
| Yes | 21 | 24 | 12 | 19 | 76 |
| No | 39 | 40 | 45 | 40 | 164 |
| Unknown | 0 | 0 | 1 | 0 | 1 |
1 further baseline measures are reported on the registry.
The record gives a start of Sep 2005, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Paclitaxel